The activity of MK was measured spectrophotometrically by coupling the formation of ADP to the reactions of pyruvate kinase and lactate dehydrogenase. The rate of ADP formation was quantitated by the reduction of absorbance (OD340) due to the oxidation of NADH to NAD by lactate dehydrogenase. A kinetic assay was chosen to minimize interference by compounds that absorbed at 340 nm. Compounds were initially screened at a final concentration of 10 uM. Three hundred and twenty compounds that had the highest %inhibition were scored as hits. These hits were then tested in dose response at ten concentrations, ranging from 100 uM to 0.196 uM. To confirm that the compounds were specifically inhibiting MK and not one of the other enzymes in the assay, the hits were tested in parallel in an assay that contained only these 'coupling enzymes'. Mevalonate Kinase Protocol for 384-well HTS Final Assay Conditions in 26 ul total volume: 50 mM HEPES buffer, pH 8.0 50 mM KCl 6 mM MgCl2 5 mM ATP 0.2 mM Mevalonate 2 mM Potassium Phosphoenolpyruvate (PEP) 0.4 mM NADH 3 units/ml rabbit muscle lactic dehydrogenase (LDH) 3 units/ml rabbit muscle pyruvate kinase 60 nM Mevalonate Kinase (MK) 4% DMSO Background conditions are the same as above except that the substrate (mevalonate) is left out.  The assay is run in 384 well clear non-binding plates. Fifteen ul substrate/background is added to plates using the BeckmanCoulter Biomek FX liquid handling workstation.  Compounds are then added in 1 ul volumes using the FX. The reaction is initiated by the addition of 10 ul of MK using the Titertek Multidrop peristaltic pipetting platform. The test plate was immediately transferred to a Perkin Elmer Envision microplate reader and the decrease in absorbance was measured at 340 nm every 16 seconds for 144 seconds. Each plate had 64 control wells in the four outside columns and 32 containing the complete reaction mixture with carrier control (full reaction) and 32 in which the PS had been left out (background). The 'coupling enzyme' assays were performed as above by replacing MK with hexokinase.
bao:BAO_0000540 "555" ; # "is confirmatory assay of" -> "555"
bao:BAO_0000809 bao:BAO_0000030 ; # "has confirmatory assay" -> "confirmatory assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000411 ; # "assay measurement type" -> "kinetic assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000294 ; # "has participant" -> "kinase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0002005 ; # "is bioassay type of" -> "kinase activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0000139 ; # "has assay method" -> "direct enzyme activity measurement method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> bao:BAO_0000484 ; # "has assay design method" -> "enzyme inhibition"
bao:BAO_0000207 bao:BAO_0000049 ; # "has detection method" -> "spectrophotometry method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "To screen for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae" ; # "screening campaign name" -> "To screen for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae"
bao:BAO_0002853 "Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK Dose Response" ; # "has assay title" -> "Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK Dose Response"
bao:BAO_0002867 bao:BAO_0000515 ; # "has assay footprint" -> "384 well plate"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Kinetic read at 16 second intervals for 144 seconds" ; # "enzyme reaction time" -> "Kinetic read at 16 second intervals for 144 seconds"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
bao:BAO_0000740 "full reaction condition without Mevalonate" ; # "has assay control" -> "full reaction condition without Mevalonate"
bao:BAO_0000740 bao:BAO_0000334 ; # "has assay control" -> "background control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Thomas Leyh" ; # "material entity assay provider" -> "Thomas Leyh" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000693 ; # "has participant" -> "HEPES" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35225> ; # "has role" -> "buffer"
bao:BA0_0090012 bao:BAO_0000967 ; # "has participant" -> "Mevalonate"
bao:BA0_0090012 bao:BAO_0000997 ; # "has participant" -> "Potassium phosphoenolpyruvate" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 "Mevalonate kinase" ; # "has participant" -> "Mevalonate kinase"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_373153> ; # "has organism" -> "Streptococcus pneumoniae D39"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q04M89" ; # "uniprot ID" -> "Q04M89"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "373153" ; # "NCBI taxonomy ID" -> "373153"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002622 bao:BAO_00020127 ; # "has purity value" -> "purified"
bao:BA0_0090012 "NAD" ; # "has participant" -> "NAD"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000568 "340 nanometer" ; # "absorbance wavelength" -> "340 nanometer"
bao:BAO_0000208 bao:BAO_0000190 ; # "has endpoint" -> "IC50"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "4" ; # "PubChem TID" -> "4"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "8" ; # "PubChem TID" -> "8"
bao:BAO_0002845 "2" ; # "has repetition point-number" -> "2"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie" ; # "Annotated by" -> "kunie"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "6" ; # "PubChem TID" -> "6"
